Advertisement
U.S. markets closed

Annovis Bio, Inc. (ANVS)

NYSE - NYSE Delayed Price. Currency in USD
9.10+0.23 (+2.59%)
At close: 04:00PM EST
9.45 +0.32 (+3.53%)
After hours: 04:08PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close8.87
Open9.24
Bid8.50 x 1000
Ask9.47 x 900
Day's Range8.77 - 9.45
52 Week Range5.42 - 23.89
Volume100,550
Avg. Volume320,071
Market Cap96.277M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-4.84
Earnings DateApr 01, 2024 - Apr 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Annovis Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/14/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

    MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRK

  • Insider Monkey

    12 $10 Stocks That Will Triple

    In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan, the global outlook for securities markets in 2024 suggests a more positive scenario compared to the previous year, with […]

  • GlobeNewswire

    Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

    MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). "The completion of the Alzheimer’s study marks a significant step in our efforts to bring new therapies to patients,” said Maria Maccecchini, Ph.D., Founder, Presid